GlassScriptPhysician profile
Whitney D Perry
NPI 1669773511
$5,076.81
in general payments reported to CMS, 2019-2025
50 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $938 · 2023: $1,135 · 2024: $1,353 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,586.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $731.29 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $498.18 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $352.50 | 2021-2025 | Reblozyl, Opdivo |
| Amgen INC. | $307.35 | 2021-2024 | Blincyto, Kyprolis |
| Daiichi Sankyo INC. | $239.20 | 2021-2025 | Enhertu, Injectafer |
| Incyte Corporation | $232.42 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Abbvie INC. | $203.61 | 2023-2025 | |
| Pfizer INC. | $183.42 | 2022-2025 | |
| Janssen Biotech, INC. | $180.63 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Astellas Pharma US INC | $180.52 | 2021-2025 | Vyloy, Padcev, Xtandi |
| Genentech, INC. | $144.87 | 2024 | Itovebi |
| Genzyme Corporation | $141.45 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $125.71 | 2021-2023 | Monoferric |
| Gilead Sciences, INC. | $121.83 | 2022-2024 | Trodelvy |
| Coherus Oncology, INC. | $115.37 | 2022-2024 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.